SILO

Silo Pharma ($SILO) CEO Aggressively Buying Despite 80% Stock Decline... "Hidden Biotech Gem Discovery"

11/21/2025 23:51

Silo Pharma ($SILO) CEO Eric Weisblum's persistent share purchases amid a dramatic stock decline are sending a powerful confidence signal to investors. His November 2025 acquisition of 13,000 shares for approximately $4,847 suggests significant undervaluation potential at current price levels. Silo Pharma specializes in developing central nervous system disorder treatments with an innovative pipeline including SPC-15 for PTSD, SP-26 ketamine implant for fibromyalgia, and SPC-14 for Alzheimer's disease. The company leverages research collaborations with Columbia University and University of Maryland Baltimore, distinguishing itself through psychedelic-based therapeutic approaches in an emerging field gaining scientific and investor attention. Weisblum's buying pattern reveals deep conviction in the company's prospects. He purchased 5,000 shares in June 2024 when stock traded at $1.08-1.11, added 7,500 shares in November-December 2024 at $0.84-0.95 during decline periods, and most notably bought 10,000 shares in May 2025 when price hit $0.43. His recent November 2025 purchases of 13,000 shares at $0.36-0.41 demonstrate unwavering confidence in bottom-fishing strategy. The CEO's aggressive buying rests on solid fundamentals. Silo maintains robust financial health with $5.87 million cash and zero debt, yielding an impressive 8.70 current ratio. This conservative balance sheet provides over one year of operational runway - rare stability among small-cap biotech peers facing capital constraints. More intriguingly, Silo has pioneered innovative treasury management by investing in Bitcoin, Ethereum, and Solana starting September 2025, followed by strategic investment in Alphaledger's T12 Fund - a tokenized real-world asset vehicle on Solana blockchain. This unprecedented move in biotech aims to generate consistent 12% target returns while reducing portfolio volatility through diversified income streams. Clinical pipeline developments support insider optimism. Lead candidate SPC-15, an intranasal PTSD treatment, progresses toward 2026 IND application following November partnership with Allucent. SP-26 ketamine implant achieved all primary and secondary endpoints in April 2025 fibromyalgia study with no implant-related adverse events. The company continues expanding IP portfolio with Australian patent grants and additional applications strengthening future licensing potential. However, significant risks persist. Annual operating cash burn of $4.8 million against minimal revenue ($72K TTM) highlights ongoing losses typical of pre-revenue biotech. Stock volatility remains extreme - surging to $3.47 in July 2024 before crashing to $0.43 in May 2025, representing 226% peak-to-trough decline. Current valuation metrics suggest compelling risk-reward dynamics. Trading at 0.97x book value with negative enterprise value of -$1.1 million, investors essentially receive pipeline assets at no additional cost above net cash value. This presents rare opportunity in biotech where promising assets trade below liquidation value. Near-term catalysts include SPC-15 IND application progress, additional SP-26 clinical data, and cryptocurrency treasury performance updates. Early 2026 GLP toxicology study results will provide crucial pipeline validation. Long-term prospects benefit from growing psychedelic therapeutics market and high unmet medical needs in PTSD treatment. FDA's increasingly open stance toward psychedelic medicines enhances SPC-15's approval probability while innovative delivery mechanisms differentiate Silo's approach. The CEO's unwavering commitment through extreme volatility reflects deep insider knowledge and long-term vision confidence. For risk-tolerant investors, Silo Pharma presents compelling opportunity combining biotech upside potential with pioneering treasury diversification at historically attractive valuations.